Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Becton DickinsonXSWX:BDX 73 Debt-to-EBITDA is 6.10 as of Mar. 2026, which is 41% above its 10-year median of 4.33. GuruFocus rates XSWX:BDX with a GF Score™ of 73/100 and a GF Value™ of CHF152.74. The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Becton Dickinson ranks worse than 73.45% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Becton Dickinson's Debt-to-EBITDA or its related term are showing as below:
XSWX:BDX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.61 Med: 4.33 Max: 7.3
Current: 3.66
During the past 13 years, the highest Debt-to-EBITDA Ratio of Becton Dickinson was 7.30. The lowest was 3.61. And the median was 4.33.
XSWX:BDX's Debt-to-EBITDA is ranked worse than 73.45% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs XSWX:BDX: 3.66
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Becton Dickinson Debt-to-EBITDA Related Terms
Becton Dickinson Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BDX vs MDLN, RMD, WST: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Becton Dickinson's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Becton Dickinson (XSWX:BDX) has a Debt-to-EBITDA of 6.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Becton Dickinson. This is 41% above median its historical median of 4.33. Over the past decade, Becton Dickinson's Debt-to-EBITDA has ranged from 3.61 to 7.30. According to the industry distribution chart, Becton Dickinson ranks #343 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 73.4%.
Is Becton Dickinson's Debt-to-EBITDA too high?
Becton Dickinson's current Debt-to-EBITDA of 6.10 is 41% above median its 10-year median of 4.33. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 7.30. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Becton Dickinson's value of 6.10 is 288.5% above this industry median. Based on the distribution chart, Becton Dickinson ranks #343 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Becton Dickinson has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's Debt-to-EBITDA compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #343 out of 467 companies for Debt-to-EBITDA. This places Becton Dickinson in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Becton Dickinson's value of 6.10 is 288.5% above this benchmark. Historically, Becton Dickinson's own Debt-to-EBITDA has ranged from 3.61 to 7.30 over the past decade. While the company's 10-year median is 4.33 vs. the industry median of 1.57, Becton Dickinson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current Debt-to-EBITDA of 6.10 is 288.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Becton Dickinson. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current Debt-to-EBITDA is 6.10, which is 41% above median its own 10-year median of 4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current Debt-to-EBITDA of 6.10. The stock's GF Value™ is CHF152.74, compared to a current price of CHF127.84 — trading 16.3% below its estimated fair value. The current Debt-to-EBITDA is 6.10, which is 41% above median its 10-year median of 4.33 and 288.5% above the Medical Devices & Instruments industry median of 1.57. Becton Dickinson's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current Debt-to-EBITDA is 6.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of CHF127.84 is trading 16.3% below its estimated GF Value™ of CHF152.74.
Key valuation signals for XSWX:BDX:
Debt-to-EBITDA: 6.10 (41% above median its 10-year median of 4.33)
GF Value™: CHF152.74 vs. price of CHF127.84 (16.3% below fair value)
Industry Position: 288.5% above the Medical Devices & Instruments median (#343 of 467)
No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
73GF Score
Get the complete analysis for XSWX:BDX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BDX has been successfully added to your 
